Intrinsic cellular resistance to BCR::ABL1 inhibitors
The clinical implementation of BCR::ABL1 tyrosine kinase inhibitors (TKI) for the treatment of chronic myeloid leukemia (CML) represents one of the big successes of mechanism-based cancer therapy.
Evidence level: Korai humán adat. Kis vagy feltáró emberi adat.
Related signals
- Treatment of chronic myeloid leukemia chronic phase patients in third-line setting and beyond: recommendations from a Belgian expert panel in 2025
- Chronic myeloid leukemia: Current guidelines for diagnosis and management
- Nilotinib versus imatinib with early switch from imatinib to nilotinib to obtain treatment‑free remission in newly diagnosed chronic myeloid leukemia patients: the analysis of the first co‑primary endpoint
- Information about Project 4: Chronic myeloid leukemia (CML)
- Prevalence and characterization of germline RAS pathway variants in children with chronic myeloid leukemia